Half-year report · HY
2590.TEDINET S100Z07E
Period2026-01-21 → 2026-07-20
Filed2026-09-03
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥120.1bn | 2026-01-21 → 2026-07-20 | Cons. | Net sales |
| Revenue | ¥241.2bn | 2025-01-21 → 2026-01-20 | Cons. | Net sales (5-year summary) |
| Revenue | ¥117.7bn | 2025-01-21 → 2025-07-20 | Cons. | Net sales |
| Operating income | ¥6.7bn | 2026-01-21 → 2026-07-20 | Cons. | Operating income |
| Operating income | ¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Operating income |
| Ordinary income | ¥4.3bn | 2026-01-21 → 2026-07-20 | Cons. | Ordinary income |
| Ordinary income | ¥1.5bn | 2025-01-21 → 2026-01-20 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Ordinary income |
| Profit before tax | ¥4.3bn | 2026-01-21 → 2026-07-20 | Cons. | Income before income taxes |
| Profit before tax | ¥69m | 2025-01-21 → 2025-07-20 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.8bn | 2026-01-21 → 2026-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥30.3bn | 2025-01-21 → 2026-01-20 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.4bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.9bn | 2026-01-21 → 2026-07-20 | Cons. | Profit loss |
| Net income | −¥1.9bn | 2025-01-21 → 2025-07-20 | Cons. | Profit loss |
| Total assets | ¥166.4bn | at 2026-07-20 | Cons. | Assets |
| Total assets | ¥162.8bn | at 2026-01-20 | Cons. | Assets |
| Total assets | ¥196.2bn | at 2025-07-20 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥96.6bn | at 2026-07-20 | Cons. | Liabilities |
| Total liabilities | ¥97.9bn | at 2026-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥69.8bn | at 2026-07-20 | Cons. | Net assets |
| Net assets / equity | ¥64.9bn | at 2026-01-20 | Cons. | Net assets |
| Net assets / equity | ¥90.7bn | at 2025-07-20 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥24.1bn | at 2026-07-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥28.0bn | at 2026-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥23.3bn | at 2026-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥27.9bn | at 2026-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.9bn | at 2025-07-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.6bn | at 2025-01-20v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.9bn | 2026-01-21 → 2026-07-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥11.4bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.1bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.8bn | 2026-01-21 → 2026-07-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥12.1bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.2bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.4bn | 2026-01-21 → 2026-07-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥300m | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.6bn | 2025-01-21 → 2025-07-20 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥88.34 | 2026-01-21 → 2026-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-957.83 | 2025-01-21 → 2026-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-43.05 | 2025-01-21 → 2025-07-20 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.5% | at 2026-07-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.5% | at 2026-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2025-07-20 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 50
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2026-01-21 → 2026-07-20 | −¥121m |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-21 → 2026-07-20 | −¥121m |
| Reconciling Itemsreconciling | segment profit | 2026-01-21 → 2026-07-20 | −¥821m |
| Domestic Beverage Businessreportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥67.6bn |
| Domestic Beverage Businessreportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥67.6bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2026-01-21 → 2026-07-20 | ¥41m |
| Domestic Beverage Businessreportable segment | segment profit | 2026-01-21 → 2026-07-20 | ¥2.1bn |
| Dy Do Pharmareportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥473m |
| Dy Do Pharmareportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥473m |
| Dy Do Pharmareportable segment | segment profit | 2026-01-21 → 2026-07-20 | −¥80m |
| Food Businessreportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥9.5bn |
| Food Businessreportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥9.5bn |
| Food Businessreportable segment | revenue intersegment | 2026-01-21 → 2026-07-20 | ¥3m |
| Food Businessreportable segment | segment profit | 2026-01-21 → 2026-07-20 | ¥35m |
| International Beverage Businessreportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥36.0bn |
| International Beverage Businessreportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥36.0bn |
| International Beverage Businessreportable segment | segment profit | 2026-01-21 → 2026-07-20 | ¥5.2bn |
| Pharmaceutical Related Businessreportable segment | revenue | 2026-01-21 → 2026-07-20 | ¥6.5bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2026-01-21 → 2026-07-20 | ¥6.5bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2026-01-21 → 2026-07-20 | ¥76m |
| Pharmaceutical Related Businessreportable segment | segment profit | 2026-01-21 → 2026-07-20 | ¥267m |
| —segment total | revenue | 2026-01-21 → 2026-07-20 | ¥120.2bn |
| —segment total | revenue external | 2026-01-21 → 2026-07-20 | ¥120.1bn |
| —segment total | revenue intersegment | 2026-01-21 → 2026-07-20 | ¥121m |
| —segment total | segment profit | 2026-01-21 → 2026-07-20 | ¥7.6bn |
| Reconciling Itemsreconciling | revenue | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-21 → 2025-07-20 | −¥228m |
| Reconciling Itemsreconciling | segment profit | 2025-01-21 → 2025-07-20 | −¥506m |
| Domestic Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| Domestic Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥71.5bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥65m |
| Domestic Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥2.0bn |
| Dy Do Pharmareportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥263m |
| Dy Do Pharmareportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥263m |
| Dy Do Pharmareportable segment | segment profit | 2025-01-21 → 2025-07-20 | −¥184m |
| Food Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| Food Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥10.4bn |
| Food Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥3m |
| Food Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥530m |
| International Beverage Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| International Beverage Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥28.8bn |
| International Beverage Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥3.1bn |
| Pharmaceutical Related Businessreportable segment | revenue | 2025-01-21 → 2025-07-20 | ¥7.0bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2025-01-21 → 2025-07-20 | ¥6.8bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥158m |
| Pharmaceutical Related Businessreportable segment | segment profit | 2025-01-21 → 2025-07-20 | ¥463m |
| —segment total | revenue | 2025-01-21 → 2025-07-20 | ¥117.9bn |
| —segment total | revenue external | 2025-01-21 → 2025-07-20 | ¥117.7bn |
| —segment total | revenue intersegment | 2025-01-21 → 2025-07-20 | ¥228m |
| —segment total | segment profit | 2025-01-21 → 2025-07-20 | ¥1.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 530
| Item | Context | Value | Unit |
|---|---|---|---|
| Description issued shares voting rights | InterimInstant_SharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_SharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)ダイドーグループホールディングス株式会社 | |
| Address of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)大阪市北区中之島 二丁目2番7号 | |
| Name of shareholder treasury shares etc | InterimInstant_Row2Member | Original text (Japanese)株式会社秋田ダイドー | |
| Address of shareholder treasury shares etc | InterimInstant_Row2Member | Original text (Japanese)秋田県秋田市御野場二丁目1番7号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | InterimDuration | Text · Plus | |
| Note on independent audit financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated balance sheet (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of comprehensive income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Notes accounting treatments specific to semi annual financial statements type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes additional information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Notes regarding income taxes for global minimum tax (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |